Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ND-L02-s0201 Injection
ND-L02-s0201 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Module A | EXPERIMENTAL | Lyophilized Formulation |
| Module B | EXPERIMENTAL | Frozen Formulation |
| Experimental: Arm A | EXPERIMENTAL | Once a week dosing |
| Experimental: Arm B | EXPERIMENTAL | Twice a week dosing |
| Name | Type | Description |
|---|---|---|
| ND-L02-s0201 | DRUG | Specified dose on specified day |
| ND-L02-s0201 Injection | DRUG | - |
Inclusion Criteria: * Subject is in good health, as determined by the Investigator * Subject consumes an average of no more than 2 alcoholic drinks per day within the 6 months before administration of study drug * Subject has serum calcium and parathyroid hormone (intact) within the limits of the n...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-581, VX-272 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
ND-L02-s0201 is an investigational small molecule developed by Bristol-Myers Squibb Company (ticker BMY). It has been studied in clinical trials for fibrosis, including moderate to extensive hepatic fibrosis classified as METAVIR F3-4. It is not an approved therapy and remains in clinical development.
ND-L02-s0201 has been studied for the treatment of fibrosis, specifically moderate to extensive hepatic fibrosis scored as METAVIR F3-4. The clinical program evaluated its safety, tolerability, and effects in the body. It is investigational and has not been established as a treatment for any condition.
ND-L02-s0201 is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored the clinical studies of the asset, including a Phase 1 study in healthy volunteers and a Phase 1b/2 study in patients with moderate to extensive hepatic fibrosis.
ND-L02-s0201 is in Phase 1 development. Its clinical program includes a completed Phase 1 study and a completed Phase 1b/2 study. The drug is investigational and has not been approved by the FDA for any indication.
ND-L02-s0201 has been evaluated in two completed trials: NCT03241264, a Phase 1 study of safety, tolerability, and effects on the body in 12 healthy volunteers, and NCT02227459, a Phase 1b/2 open label, repeat dose, dose escalation study in 25 subjects with moderate to extensive hepatic fibrosis (METAVIR F3-4) conducted in the United States and Bulgaria.
Yes. ND-L02-s0201 Injection is another name for ND-L02-s0201. The trial listing for NCT02227459 refers to the asset as ND-L02-s0201 Injection, while other study records use the shorter name ND-L02-s0201. Both refer to the same investigational small molecule developed by Bristol-Myers Squibb.